Ignite Creation Date:
2025-12-24 @ 9:19 PM
Ignite Modification Date:
2025-12-26 @ 7:11 AM
Study NCT ID:
NCT00418704
Status:
COMPLETED
Last Update Posted:
2013-10-01
First Post:
2007-01-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Elderly Independent Patients With Non Small Cell Lung Cancer (NSCLC)
Sponsor:
Groupe Francais De Pneumo-Cancerologie
Organization:
Study Overview
Official Title:
A Multicenter Randomized Phase II Trial in NSCLC Stage IV and IIIB (T4 With Pleural Effusion) in Elderly Independent Patients the Schedule Docetaxel / Gemcitabine First Line Following by Erlotinib When Progression Versus Erlotinib First Line Following by/ Gemcitabine When Progression.
Status:
COMPLETED
Status Verified Date:
2013-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine duration before progression of first-line treatment chemotherapy following erlotinib in second-line comparing erlotinib in first-line following chemotherapy in second-line in old patients with none small cell lung cancer.
Detailed Description:
A multicenter phase II trial , prospective, randomized, open, non comparative
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: